Loss of Anti–SARS-CoV-2 Antibodies in Mild Covid-19 | NEJM
Correspondence from The New England Journal of Medicine — Loss of Anti–SARS-CoV-2 Antibodies in Mild Covid-19
Related Articles
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel…
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel…
